Targeted therapy in CLL: changing the treatment paradigm
Oncotarget
.
2019 Jun 18;10(40):4002-4003.
doi: 10.18632/oncotarget.26964.
Authors
Christof Schneider
1
,
Daniela Steinbrecher
1
,
Stephan Stilgenbauer
1
2
Affiliations
1
Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany.
2
Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany.
PMID:
31258844
PMCID:
PMC6592289
DOI:
10.18632/oncotarget.26964
No abstract available
Keywords:
BCL2; TP53; chronic lymphocytic leukemia; deletion 17p; venetoclax.
Publication types
Editorial